Drug Trial Radar · NCT04235816
Improving Care Through Azithromycin Research for Infants in Africa
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,560
Actual
Start
Mar 15, 2021
Primary completion
Sep 11, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Barcelona Institute for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Sierra Leone; Bill and Melinda Gates Foundation; Ministry of Health and Sanitation, Sierra Leone; La Caixa Foundation
- First posted
- Jan 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 8 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone . Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age. Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.
Conditions
- Child Mortality
Interventions
AzithromycinDrug
Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
PlaceboDrug
Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of all-cause mortalityTime frame: 18 months of age
Locations
1 site in 1 country. Site status is shown where the registry gives one.
College of Medicine and Allied Health Sciences
Freetown, Sierra Leone
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.